Using Data, To Make Workflows Smarter

Streamlining Healthcare Associated Surgical Site Infection (SSI) Surveillance Reporting

Lauren Mitchell, Pauline Bass and Alfred Health Infectious Disease Data Team



No conflict of interest

The Impact of Surgical Infections

- SSIs are one of the most common complications related to surgery
- 3% of surgical patients in Australia may experience an SSI
- Diagnosis of SSI contributes to length of hospital stay and mortality
- Estimated more than 16,500 cases of SSI in Australia annually
- Average cost per patient when diagnosed is more than \$18,800

(Royle et al., 2023)



Surgical Site Infections and Surveillance

- Includes review and reporting of surgical infections
 - Application of specific assessment definitions
 - Monitoring period is between 30-90 days
 - Allows benchmarking between organisations
 - Review of local practice



The Surveillance Data

- Surveillance reviews occur in hospitals with >100 beds
- Public and Private Hospitals are required to participate
- Data submitted to an independent state-wide centre (VICNISS)
- Data is risk adjusted to allow benchmarking

(VICNISS, 2023)



The Classification Criteria

Skin

Subcutaneous Tissue

Deep Soft Tissue (fascia/muscle)

Organ/Space

Superficial incisional SSI

Deep incisional SSI

Organ/Space SSI



The Alfred

- One of Australia's busiest Emergency and Trauma centres
- Victoria's largest Intensive Care Unit
- 18 state-wide services
- Elective & Emergency surgery
- 3 Operating Suite sites



The Analysis

- Cardiothoracic, Orthopaedic and Colorectal SSI reviews
- Surgical Site Infection appraisals are often time-consuming
- Reviews require inspection of large volumes of documentation
- Each assessment requires risk identification and appraisal
- Streamlining systems became a priority for our service



The Modifications

- Collaboration with our in-house data team at Alfred Health
- Development of an electronic database
- Automation and auto population of surveillance forms
- Funding for full-time role, with primary focus on Surveillance



Denominator form

Surgical Procedure (Denominator) THIS DATA MUST BE SUBMITTED ONLINE USING A VICNISS WEBFORM

Patient & Pro	cedur	e Deta	ils	H	Hospital	name:				MRN (UR No.):							
Sex: □ M	□F		0	DOB:			Admi	it Date:		Discharge Date:							
Procedure	DAAA	□В	RST	□СВО	GB □CI	HOL [CRAN	□FPOP	□GAS1	п	PRO DK	PRO I	PACE	□V	'HYS		
Group:	□APP	Y DC	ARD	□CBO	GC □C	OLO [CSEC	□FUSN	HERN	N □H	YST DL/	AM I	SB	□V	SHN		
ACHI codes/s	i			_ OR	MBS Cod	de/s:			OR N	ame of	Procedur	e:			_		
Procedure Da	St	art Tim	ne¹:		□NA	Finish Time	e¹:	□ NA Surgeon (coded):									
ASA Score: 1 2	2 3 4	5 NA	Wo	und Cla	ass: C CC	CO D	NA	Height (me	etres):		□ NA W	eight: (k	g):		□NA		
General Anaes	thesia:	□Y	□N	Eme	ergency:	□Y	□N [Diabetes Mel	llitus:	□Y	□N	Traum	a: 🗆 '	Y 🗆 1	^		
Closure Technique: Primary Non-primary Laparoscope: Y N Robotic Assist: Y N																	
HPRO/KPRO/BR	ST/HERI	N: 🗆	Left	□ Righ	t 🗆 Bil	ateral/2 In	ncisions ²	CSEC: D	uration	of Labou	r (hours):		or [No la	bour		
HPRO/KPRO:	(select or	ne) 🗆	Total		□ Partial	□ Res	urfacing	(HPRO only)									
	(select or	ne) 🗆	Primar	y 🗆	Revision –	if revision	, was it	associated with	h prior ir	nfection a	at index joins	(? □ Y	es 🗆	No	□ NA		
FUSN: Appro	ach/Teo	:hnique	□ Ar	terior	□ Poster	ior 🗆 A	nterior 8	& Posterior	□NA								
Spinal	Level:	□ Atlas-a	oxis 🗆 /	Atlas-axis/	Cervical I	Cervical	□ Cen	vical/Dorsal/Dorsa	olumbar	□ Dorsal	/Dorsolumbar	□ Lumba	r/Lumbo	acral	□ NA		
Surgical Antir	microb	ial Pro	phyla	xis (SA	P) Pro	phylac	tic Anti	ibiotic Adm	inister	ed:	□ Yes	□No		□ N/	A		
Antibio (Generic r			Dose (mg)	Route			Tim	ne of Adminis	stration			Ant	tibiotic (Continu	ued:		
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,				Time	If exact t		Beyond end of If yes,									
					Given							surger	у	>24 post			
1 st Dose:																	
I" Dose:																	
I" Dose:		П				□ >1hr pr					rior to incision	ΠY	□N	ПΥ	ΠN		
I" Dose:		\exists				On indi	uction ior to inc	☐ After I	ncision	ithin 1hr p	NA rior to incision	□ Y	□N □N	□Y □Y	□N □N		
I" Dose:						On indi	uction for to incluction for to include	□ After I	ncision Wincision W	ithin 1hr po	NA rior to incisior NA rior to incisior	ı OY	□N	ПΥ	□N		
		пм				On indi	uction for to incluction for to incluction	After I	ncision Wincision Wincision Wincision	fithin 1hr po fithin 1hr po	NA rior to incisior NA	1	□N □N	□Y □Y	□N □N		
Vancomycin ³	ПΥ	□ N				On indi > 1hr pr On indi > 1hr pr On indi > 1hr pr On indi	uction ior to inci uction ior to inci uction prior to inci prior to inci	After I	Incision Wincision Wincision at 5 to sti	fithin 1hr po fithin 1hr po	NA rior to incisior NA rior to incisior NA r to incision sion □N	O Y	□N □N	□Y □Y □Y	□N □N		
Vancomycin ³ Clindamycin ³	ПΥ	□N				On indi >1hr pr On indi >1hr pr On indi >1hr pr On indi >120min p <15min p >120min p >120min p >120min p On induct	uction ior to inci- uction ior to inci- uction prior to inci- prior to inci- prior to inci- prior to inci- prior to inci-	After I	Incision Wincision Wincision 215 to s1 duction 5 to s120rr ision	fithin 1hr p	NA rior to incision NA rior to incision NA r to incision sion CN incision NA incision	Y	□N □N □N	_Y _Y _Y	□N □N □N □N		
Vancomycin ³ Clindamycin ³ Gentamycin ³	□ Y	□ N				On indi > 1hr pr On indi > 1hr pr On indi > 1hr pr On indi > 120min p < 15min p > 120min p > 120min p > 120min p > 120min p On induct > 120min p	uction ior to inci- uction ior to inci- uction orier to inci- orier to inci- sion orier to inci- sion orier to inci- sion orier to inci- sion	After I	Incision Wincision Latis to stand duction S to s120mission 5 to s120mission 5 to s120mission 5 to s120mission	fithin 1hr pr	NA rior to incision NA rior to incision NA r to incision Sion INI incision NA incision NA incision	- Y	ON ON ON	_Y _Y _Y _Y	ON ON ON		
Vancomycin ³ Clindamycin ³ Gentamycin ³ Metronidazole ³	□ Y □ Y □ Y	□ N □ N □ N	ue >4hru	after ini	tial antibiotic	On indi > 1hr pr On indi > 1hr pr On indi > 1hr pr On indi > 120min p < 15min p > 120min p > 120min p > 120min p > 120min p On induct > 120min p On induct	uction ior to inci uction ior to inci uction ior to inci uction prior to inci iorior to inci iorioriorioriorioriorioriorioriorioriori	After I	Incision Wincision Wincision 1 ≥15 to ≤1 duction 5 to ≤120rrision 5 to ≤120rrision 5 to ≤120rrision	fithin 1hr p	NA rior to incision NA rior to incision NA rior to incision Sion Incision NA Incision NA Incision NA	Y	□N □N □N	_Y _Y _Y	□N □N □N □N		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t	Y Y	N N N			tial antibiotic	On indu > Thr pr On indu > Thr pr On indu > Thr pr On indu > 120min p < 120min p < 120min p < 120min p On induct > 120min p On induct > 120min p On induct > 120min p	uction ior to inci uction ior to inci uction ior to inci uction prior to inci prior to inci son ative dose	After After Ision	Incision Wincision Latis to stand duction S to s120mission 5 to s120mission 5 to s120mission 5 to s120mission	fithin 1hr pp	NA rior to incision NA rior to incision NA r to incision Sion ON incision NA incision NA incision NA incision NA	- Y	ON ON ON ON	_Y _Y _Y _Y _Y	ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	□ N □ N □ N ry contin	g of Cep	hazolin 4	hrs from the	On indu > 1hr pr On indu > 1hr pr On indu > 120min p <15min s > 120min p <15min s > 120min p On induct pre-opera	uction ior to inci uction ior to inci uction ior to inci uction prior to ind prior to ind son	After After Ision	Incision Wincision Wincision Wincision Wincision Wincision Wincision Stockholm Stockholm Stockholm Stockholm Wission West West West West West Wincision West West West West West West Wincision West West West West West West West West	fithin 1hr pr	NA rior to incision NA NA rior to incision NA re incision NA incision NA incision NA incision NA incision NA o D D Not	Y Y Y Y Y Y Y Y Y Y Y Required*	ON ON ON ON ON	Y	ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t	Y Y Y Y Y He surge	□ N □ N □ N ry contin	g of Cep on to SA	hazolin 4	hrs from the	On indu > 1hr pr On indu > 1hr pr On indu > 120min p <15min s > 120min p <15min s > 120min p On induct pre-opera	uction ior to inci uction ior to inci uction ior to inci uction prior to ind prior to ind son	□ After I ision □ After I isi	Incision Wincision Wincision Wincision Wincision Wincision Sito statement of the statement	fithin 1hr pr	NA nior to incision NA nior to incision NA r to incision NA incisi	Y Y Y Y Y Y Y Y Y Y Y Required*	ON ON ON ON ON	Y	ON ON ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t if yer Other Antibiotic	Y Y Y Y Y He surge	N N N N N N N N N N N N N N N N N N N	g of Cep on to SA	hazolin 4 P (listed	hrs from the above), w	On Indi Shr pr In Indi Shr pr On Indi Shr pr	uction ior to inci uction ior to inci uction ior to inci uction erior to inci uction erior to inci erior to inci sion erior to	□ After I ision □ After I isi	Incision Wincision Wincision Wincision Wincision Wincision Sto state of duction Sto state of the	ithin the put 20mins prior 20mins prior 20mins prior to thins prior to this prior to No No to surge	NA nior to incision NA nior to incision NA r to incision NA incisi	Y	ON O	Y	ON ON ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t if yer Other Antibiotic	Y Y Y Y Y He surge	N N N N N N N N N N N N N N N N N N N	g of Cep on to SA	hazolin 4 P (listed	hrs from the above), w	On Indi > Thr pr On Indi > 120min p On Indi > 120min p	uction ior to inci uction ior to inci uction ior to inci uction ior to inci uction prior to inci prior to inci ior prior	After Indiana Af	Incision Wincision Wincision Wincision Wincision Wincision 1215 to still duction 5 to stillor sision 5 to stillor sision Wes	ithin 1hr p	NA NA NA rior to incision NA rior to incision NA no color incision NA no color NA NA no color NA nosion NA nosion NA nosion NA color nosion NA	Y	N N N N N N N N N N N N N N N N N N N	Y Y Y Y Y Y Y Y Y Y Y No	ON ON ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t if yer Other Antibiotic	Y Y Y Y Y He surge	N N N N N N N N N N N N N N N N N N N	g of Cep on to SA	hazolin 4 P (listed	hrs from the above), w	On Indi Shr pr In Indi Shr pr On Indi Shr pr	uction ior to inci uction ior to inci uction ior to inci uction ior to inci uction prior to inci prior to inci ior prior	After Indiana Af	Incision William Willi	ithin 1hr p	NA NA NA NA NA NIGOT to Incision NA	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y X Required*	N N N N N N N N N N N N N N N N N N N	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	ON ON ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t if yer Other Antibiotic	Y Y Y Y Y He surge	N N N N N N N N N N N N N N N N N N N	g of Cep on to SA	hazolin 4 P (listed	hrs from the above), w	On Indi Shr pr In Indi Shr pr On Indi Shr pr	uction ior to inci uction ior to inci uction ior to inci uction ior to inci uction prior to inci prior to inci ior prior	After Indiana Af	Incision When I was a second or to incision or i	ithin 1hr p	NA NA NA NA NA NIOR to incision NA	PY P	N N N N N N N N N N N N N N N N N N N	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	ON ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2 nd Dose: Did t if yer Other Antibiotic Antibiotic (Generic	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	N N N N N N N N N N N N N N N N N N N	g of Cepi on to SA (mg)	P (listed Route	hrs from the above), w	On Indi Shir pr On Indi Shir p	uction ior to inci uction ior to inci uction ior to inci uction ior to inci uction prior to inci prior to inci ior prior	After Indiana Af	Incision Wincision Wincision Wincision Wincision 235 to a 120 mission S to a 120 mission S to a 120 mission Yes West tics prior me of Al If exact to incision or to incision or to incision or to incision West tics prior Wes	ithin the p ithin	NA NA NA NA NA NIOR to incision NA	Required Required In y Y Y Y Y Y Y Y Y Cick a box s12hrs priin tr prior to	N N N N N N N N N N N N N N N N N N N	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	ON ON ON ON		
Vancomycin³ Clindamycin³ Gentamycin³ Metronidazole³ 2nd Dose: Did till fyer Syerial Did till fyer Syerial Dose: Did till fyer Syerial Did ti	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	N N N N N N N N N N N N N N N N N N N	g of Cepi on to SA (mg)	P (listed Route	hrs from the	On Indi On Indi I have been seen and the part of the p	uction for to incide the following to th	After Indiana Af	Incision We continue to the	Ithin The p Ithin	NA rior to incision NA NA rior to incision NA NA rior incision NA NA rior incision NA rior	Required* Style="background-color: green; color: green; c	N N N N N N N N N N N N N N N N N N N	Y Y Y Y Y Y Y Y Y Y Y Y S S S S S S S S	ON ON ON ON		



^{2.} Tick if two procedures (from the same procedure group) requiring 2 incisions were performed at the same time, e.g., left and right KPRO, umbilical and femoral HERN

Vancomycin, clindamycin, gentamicin & metronidazola – to accurately assess administration compliance the estimated start time intervals are specific to these antibiotics. Select 'Not Required' in settings where creatrine clearance <10ml/min (or eGFR <10) and antibiotic re-dosing is not required.

For CBGB procedures only - indicate all infection sites and complete a separate Surgical Site Infection (Numerator) Form for each infection.

Numerator form

Surgical Site Infection (Numerator)

THIS DATA MUST BE SUBMITTED ONLINE USING A VICNISS WEBFORM

Patient & Procedure	Details	Hosp	ital name:					
MRN (UR No.):		DOB:				Procedur	e Date:	
Procedure Group:	□ AAA	□ CARD	□ CHOL	□ CSEC	□ GAST	□ HYS	T 🗆 PAC	E UHSN
	□ APPY	□ CBGB	□ COLO	□ FPOP	□ HERN	□ KPR	O 🗆 SB	
	□ BRST	□ CBGC	□ CRAN	□ FUNS	□ HPRO	□ LAN	□ VH	'S
Infection Details and (Dutcome			Date of E	vent (Infectio	n Date):		
Infection Detected:	□ During adm	nission 🗆	Readmission	(where proc	edure perfor	med)	Readmission	to other facility
	 Post dischar 	rge surveillar	nce 🗆 HI	TH				
Infection Type:	☐ Superficial i	ncisional	□ Deep inci	sional	□ Organ/S	pace		
If yes for Organ/Space	infection, what	was the Org	an/Space Site	:				
 Arterial or venous i 	nfection (VASC)		□ Myo	carditis or p	ericarditis (C	(ARD)		
 Breast abscess or n 	nastitis (BRST)		□ Oth	er infections	of the lower	respiratory	tract (LUNG)	
☐ Disc space infection	n (DISC)		□ Oste	eomyelitis (B	ONE)			
□ Endocarditis (ENDO))		□ Oth	er infection	of the male o	or female re	productive tra	act (OREP)
☐ Endometritis (EME)	D		□ Peri	prosthetic jo	int infection	(PJI)		
 Gastrointestinal tra 	ct (GIT)		□ Sinu	sitis (SINU)				
 Intracranial infection 	n (IC)		□ Spin	al abscess v	vithout meni	ngitis (SA)		
 Intraabdominal, no 	t specified elsew	here (IAB)	□ Urin	ary system i	nfection (US	1)		
 Mediastinitis (MED))		□ Vag	inal cuff infe	ection (VCUF))		
 Meningitis or ventr 	iculitis (MEN)							
Infection Present at	time of surger	y (PATOS):	□ Yes	□ No				
CBGB only: Infection	on Site(s):	Chest	□ L Radial □	R Radial	☐ L Saphe	enous 🗆 F	Saphenous	
Bilateral/2 Incision Pro	cedures Only: Lo	cation of Infe	ection: 🗆 Le	eft □ Rig	ght 🗆	Other (spec	fy):	
Pathogen Details								
Pathogen Isolated:	□ Yes □ No	Name o	of pathogen,	/s:	1.			
		If listed belo	w, complete antimio	robial susceptibilit	^{y.} 2,			
					3.			

Antimicrobial Susceptibility Gram Positive Organisms	- Rec	ord:	: S=	c								_				_		OI	_								_
Gram Positive Organisms	Г			Sus	scep	otib	le, I	=In	ter	me	diat	e, R	=R	esis	tan	t*, c	or L	J=U	Inkr	now	m						
	Cefoxitin	Cincollouacia	Ciprotokacıı	Cindamycin	Daptomydin		Doxycydine	Flucioxadilin	Contemisis - high lated teat	2	Linezolid	Methiallin		Minocycline	Maxifloracin	Oxadilin		Penidllin	Rifampidin	Toloron landon	i accipiani	Tetracydine	and and and	2000	Trimethoptim/Sulfamethoxazole	Vancomycin	
CNS (all species)						Ц							1			L				Ш	Ц		₽	Ц		L	╛
Enterococcus faecium					L					4								_			4					L	4
Enterococcus faecalis					L				L	_										L	_					L	1
Enterococcus spp.					L	1			L	_							4			L	┙					L	4
Staphylococcus aureus	\perp		\perp										\perp														
Antimicrobial Susceptibility Gram Negative Organisms Significant Susceptibility Acinetobacter spp. Escherichia coli	Amaxiallin-Clavularic Add	-	Cefalexin	Cefazolin	Celepime	Cefotaxime	Ceftazidime	Ceftazidime/Avibactam	Ceftolozane/Tazobactam	Ceftriaxone	Ciprofloxacin	Colistin	Doripenem	Doxycydine		Gentamicin	Imipenem	Imipenen/Relebactam	Levofloxacin	Meropenem	Meropenem/Vaborbadam	Minocycline	Moxifloxacin	Piperadilin-Tazobactam	Polyyxin B	Tigecycline	Tobramydin
Enterobacter spp.		Н			\dashv					Н	Н	\dashv	-		Н	+	\dashv	\dashv	\dashv	\dashv	-				\vdash	Н	
		Н			\forall				Н		Н	\dashv	\dashv		\forall	+	\dashv	\dashv	\dashv	\dashv	\dashv		Н	_	\vdash	Н	
Nedsiera SDD.		\vdash			\mathbf{H}				\vdash									- 1	- 1	- 1						_	-
Klebsiella spp. Pseudomonas aeruginosa		1			l											П			\neg	\neg					Г		




REDCap Database

ctions:	strument(s) ♥ BI Video:	Basic data entry	
Procedure Details Butting existing Record ID 62	1343.		
Record ID		621343	
Patient Details			
Case number		MRN	
			OM
Surname		Gender	○ F
Date of Birth	53 D-M-Y		
Height		Weight	
BMI			
Hospital Details			
Hospital ID	O 495 (Sandringham) 705 (Alfred) 999 (Other Location)		
Admission Date	55 D-M-Y	Discharge Date	D-M-Y
Procedure Start Date Time	D-M-Y H:M	Procedure Finish Date Time	D-M-Y H:M
Procedure Group Name	CBGB HPRO KPRO COLO Incorrect MBS code/does not meet criteria reset	MBS Item Number	
Procedure Description			Expand
Wound Class		ASA Score	
Has Diabetes Mellitus?	○ Yes ○ No	Is laparoscopic	○ Yes ○ No
Is a Robotic Assisted Surgery?	○ Yes ○ No	Is a Trauma Patient?	○ Yes ○ No
General Anaesthesia Used	○ Yes ○ No	Is an Emergency Procedure?	○ Yes ○ No
Closure Technique			
Jnit		9	
Antibiotic Prophylaxis			
s Prophylactic Antibiotic Give	n?	⊖ ○ Yes ○ No	rese

REDCap Database

lecord ID									
Procedure Details	e Details Hospital Name:								
MRN:	Date of Birth:	<u></u>							
Procedure Group:	CBGB	,							
Infection Details and Outcor	ne	Date of Event (Infection Date):							
Infection Detected: During	g admission Readmission (wh	here procedure performed) Readmission to other facility							
Infection Type: Superficial	incisional Deep incisional	Organ/Space							
lf "Yes" for Organ/Space infe	ction, what was the Organ/Spa	ace Site:							
Infection present at the time	e of sugery (PATOS):	○ Yes ® No							
		dial C L Saphenous R Saphenous parate Surgical Site Infection (Numerator) form for each infection							
Bilateral/ 2 Incision procedu	res only: Location of Infection:	CLeft Right Other							
If Other- specify:									
athogen Details									
Pathogen Details									
Pathogen isolated:		® Yes ○ No							
orm Status									
Complete?		Complete 🗸							

REDCap Database






The Notification Process

Data team run report

New laboratory specimens identified

Alert
email sent
to
clinicians










Email Notification – Patient Requiring Review





The Outcomes



Pexels

- Development of electronic database
- Timely laboratory specimen notification
- Streamlining data submission to Victorian Coordinating Centre
- Tailored workflows based on hospital specific surveillance
- Maintenance of patient confidentiality and privacy



The Future

- Additional streamlining of existing REDCap database
- Plan to automate isolate notification dates (30 90 days)
- Development of automated stakeholder correspondence email
- Streamlining information communication and distribution
- Further research and development into electronic surveillance



References

- Alfred Health. (2023, October 11). *Statewide Services*. https://www.alfredhealth.org.au/services/statewide-services
- Australian Commission on Safety and Quality in Healthcare (2018). *Healthcare Associated Infection [factsheet]*. https://www.safetyandquality.gov.au/sites/default/files/migrated/Healthcare-associated-infection-detailed-fact-sheet.pdf
- Lydeamore, M., Mitchell, B., Bucknall, T., Cheng, A., Russo, P., & Stewardson, A. (2022).

 Burden of five healthcare associated infections in Australia. *Antimicrobial Resistance and Infection Control*, 11(69), 1-7. https://doi.org/10.1186/s13756-022-01109-8
- Morikane, K., Russo, P., Lee, K., Chakravarthy, M., Ling, M., Saguil, E., Spencer, M., Danker, W., Seno, A & Edmiston Charles, E. (2021). Expert commentary on the challenges and opportunities for surgical site infection prevention through implementation of evidence-based guidelines in the Asia—Pacific Region. *Antimicrobial Resistance and Infection Control*, 10(65). https://doi.org/10.1186/s13756-021-00916-9

References

- Royle, R., Gillespie, B., Chaboyer, W., Byrnes, J., Nghiem, S. (2023). The burden of surgical site infections in Australia: A cost-of-illness study. *Journal of Infection and Public Health*, *15*(5), 792-798. http://doi.org/10.1016/j.jiph.2023.03.018.
- Russo, P., Stewardson, A., Cheng, A., Bucknall, T., Mitchell, B. (2019). The prevalence of healthcare associated infections among adult inpatients at nineteen large Australian acute-care public hospitals: a point prevalence survey. *Antimicrobial Resistance and Infection Control*, 8(114). https://doi.org/10.1186/s13756-019-0570-y
- Strobel, R., Leonhardt, M., Förster, F., Neumann, K., Lobbes, L., Seifarth, C., Lee, L., Schineis, C., Kamphues, C., Weixler, B., Kreis, M., Lauscher, J. (2021). The impact of surgical site infection—a cost analysis. *Langenbeck's Archives of Surgery, 407*(2), 819-828. http://doi.org/10.1007/s00423-021-02346-y
- VICNISS. (2023). Surgical Site Infection (SSI) Protocol. https://www.vicniss.org.au/media/2zyh14wl/ssi-protocol_sept-2023.pdf

References

Worth, L., Bull, A., Spelman, T., Brett, J., & Richards, M. (2015). Diminishing surgical site infections in australia: time trends in infection rates, pathogens and antimicrobial resistance using a comprehensive victorian surveillance program, 2002–2013. Infection Control & Hospital Epidemiology, 36(4). http://doi.org/10.1017/ice.2014.70